Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Oncternal Therapeutics Inc ONCT

Healthcare Biotechnology
Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of oncology therapies for the treatment of patients with cancers that have critical unmet medical needs. The Company’s product candidates include ONCT-534, ONCT-808, Zilovertamab, and ONCT-216. ONCT-534 is a dual-action androgen receptor inhibitor (DAARI), for the treatment of... see more

Recent & Breaking News (NDAQ:ONCT)

Oncternal Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial Results

GlobeNewswire November 9, 2023

Oncternal Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results

GlobeNewswire November 2, 2023

Oncternal Therapeutics Announces FDA Granted Fast Track Designation for ONCT-534 for the Treatment of Metastatic Castration-Resistant Prostate Cancer

GlobeNewswire October 26, 2023

Oncternal Therapeutics Adds Matthew Smith, M.D., Ph.D. to its Prostate Cancer Scientific Advisory Board

GlobeNewswire October 25, 2023

Oncternal Therapeutics Announces First Patient Dosed in Phase 1/2 Study of Dual-Action AR Inhibitor, ONCT-534, in Patients with Metastatic Castration-Resistant Prostate Cancer

GlobeNewswire October 5, 2023

Oncternal Therapeutics Announces its Prostate Cancer Scientific Advisory Board

GlobeNewswire September 7, 2023

Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2023 Financial Results

GlobeNewswire August 10, 2023

Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results

GlobeNewswire August 3, 2023

Oncternal Therapeutics Receives FDA Study May Proceed Letter for ONCT-534, its Novel Dual-action Androgen Receptor Inhibitor, for the Treatment of Patients with Advanced Prostate Cancer

GlobeNewswire August 3, 2023

Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire June 30, 2023

Oncternal Therapeutics Announces First Patient Dosed in Phase 1/2 Study of ROR1 targeting autologous CAR T, ONCT-808, in patients with relapsed or refractory aggressive B-cell lymphoma

GlobeNewswire June 6, 2023

Oncternal Therapeutics to Participate at the 2023 Jefferies Healthcare Conference

GlobeNewswire May 31, 2023

Oncternal Therapeutics Provides Business Update and Announces First Quarter 2023 Financial Results

GlobeNewswire May 4, 2023

Oncternal Therapeutics to Provide Business Update and Report First Quarter 2023 Financial Results

GlobeNewswire April 27, 2023

Oncternal Therapeutics Participating in Oppenheimer & Co.'s Virtual Fireside Chat: Discussion of ROR1 CAR T Cell Therapy in Hematological Malignancies and Solid Tumors

GlobeNewswire April 13, 2023

Oncternal Therapeutics Announces Strategic Reprioritization and Capital Preservation, Extends Cash Runway into 2025

GlobeNewswire April 3, 2023

Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire March 27, 2023

Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2022 Financial Results

GlobeNewswire March 9, 2023

Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results

GlobeNewswire March 2, 2023

Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire March 1, 2023